Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who previously took part in either the "Characterizing Cognitive Decline in Late Life Depression" study or the "Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression" study.
- People currently taking antidepressant medication, as long as the dose has stayed the same for at least 4 weeks before the MRI scan.
- People currently receiving psychotherapy (individual or group talking therapy), as long as at least 4 weeks of that therapy have been completed before the MRI scan.
- People taking medications that are intended to support memory or thinking (sometimes called cognitive enhancing medications).
Who may not be able to join:
- No specific exclusion criteria were listed in the official criteria provided (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Scott Mackin, PhD, University of California, San Francisco
Phone: (415) 300-0582
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.; Rate of Change in expressive language as measured by the Boston Naming Test using total correct.; Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.; Change in brain structure using magnetic resonance imaging (MRI); Extent of amyloid deposition as measured by florbetapir; Extent of tau deposition as measured by flortaucipr
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.